7 Stocks with Largest Change in # of BHFs Holding Them in Q2 🆚 Q1 2024
Big moves in Q2 biopharma focused hedge fund holdings!
📌 7 stocks had the largest change in the number of BHFs holding them in Q2 🆚 Q1 2024...
We track the top 34 biopharma-focused hedge funds (BHFs) 👇
⬆️ Companies with 4+ increases:
⬇️ While, companies with 3+ decreases:
Market cap: $788.2M
Quarters cash: 3
Short interest: 9.42%
Q2-Q1 change in the number of BHFs holdings: +7
Q2-Q1 change in the sum of % ownership for all BHFs combined: +34
👨🔬 2 Noteworthy clinical trials:
→ Naporafenib / NRASm melanoma / Phase 3
→ Naporafenib / Pan-RAS Q61X tissue agnostic / Phase 1b
MOA: Naporafenib is BRAF/CRAF inhibitor (small molecule)
🗓️ Next readouts:
→ 2025 (Ph 3 stage 1 randomized dose optimization)
→ Q4 2024 (Ph 1b combination data1)
Prior results 📸
Market cap: $454.5M
Quarters cash: 6
Short interest: 6.39%
Q2-Q1 change in the number of BHFs holdings: +5
Q2-Q1 change in the sum of % ownership for all BHFs combined: +25
👨🔬 4 Noteworthy clinical trials:
→ PIPE-791 / IPF / Phase 1
→ PIPE-791 / PPMS/SPMS / Phase 1
→ PIPE-307 / RRMS / Phase 2*
→ PIPE-307 / Depression / Phase 1*
*partnership w/ JNJ
🧪 MOA:
→ PIPE-791: LPA1 Antagonist (small molecule)
→ PIPE-307: M1 selective, brain penetrant, small molecule antagonist
🗓️ Next readout:
→ 2024: Phase 1b PET Study Healthy Volunteer Clinical Data (PIPE-791)
→ 2025: Phase 1b Brain & Lung PET Study Clinical Data (PIPE-791)
Prior results 📸
Market cap: $485.5M
Short interest: 2.21%
Q2-Q1 change in the number of BHFs holdings: +4
Q2-Q1 change in the sum of % ownership for all BHFs combined: +92
👨🔬 3 Noteworthy clinical trials:
→ budoprutug (TNT119) / Membranous Nephropathy / Phase 2
→ budoprutug (TNT119) / Systemic Lupus Erythematosus / Phase 1
→ budoprutug (TNT119) / Immune Thrombocytopenia / Phase 1
🧪 MOA: Budoprutug is anti-CD19 mAb
🗓️Next readout:
→ YE 2024: Present additional data from MN Phase 1b study
Prior results 📸
Market cap: $181.7M
Quarters cash: 6
Short interest: 5.19%
Q2-Q1 change in the number of BHFs holdings: +4
Q2-Q1 change in the sum of % ownership for all BHFs combined: +44
👨🔬 1 Clinical candidate:
→ Nimacimab / Obesity / Phase 2
🧪 MOA: Nimacimab 📸 CB1 receptor inhibitor antibody
🗓️ Next readouts:
→ Q2 2025: Interim data at 50% enrollment 26 weeks dosing
→ Q4 2025: Topline data full enrollment
Prior results 📸
Market cap: $4.6B
Quarters cash: 0
Short interest: 18.44%
Q2-Q1 change in the number of BHFs holdings: -3
Q2-Q1 change in the sum of % ownership for all BHFs combined: 0
⚠️ Market and BHFs? concerned re: success of recent competitive product
✅ 2 Drugs approved:
→ SYFOVRE (pegcetacoplan) / Geographic atrophy secondary to AMD / Approved: Feb 2023
→ EMPAVELI (pegcetacoplan) / paroxysmal nocturnal hemoglobinuria (PNH) / Approved: May 2021
🧪 MOA: pegcetacoplan is C3 complement inhibitor mAb
👨🔬 2 Noteworthy clinical trials:
→ EMPAVELI® (pegcetacoplan) / IC-MPGN & C3G / Phase 3
→ EMPAVELI® (pegcetacoplan) / HSCT-TMA / Phase 2
🗓️ Next readout:
→ 2024: APL-3007 (small interfering RNA silencing C3): Topline data from the Phase 1 dose escalation study
Market cap: $321.2M
Quarters cash: 5
Short interest: 6.8%
Q2-Q1 change in the number of BHFs holdings: -3
Q2-Q1 change in the sum of % ownership for all BHFs combined: +7*
*Strange data from source of SEC info showing 0% sum for funds holding in Q1
👨🔬 5 Noteworthy clinical trials:
→ KYV-101 / Lupus nephritis / Phase 1/2
→ KYV-101 / Systemic sclerosis / Phase 1/2
→ KYV-101 / Myasthenia gravis / Phase 2
→ KYV-101 / Multiple sclerosis / Phase 2
→ KYV-101 / Stiff person syndrome / Phase 2
🧪 MOA: KYV-101 is CD19 CAR T therapy
🗓️ Next readout:
→ September 2024: Neurology case reports at ECTRIMS
→ November 2024: Rheumatology KYSA Clinical Trial updates at ACR
Market cap: $2.6B
Quarters cash: 1
Short interest: 11.46%
Q2-Q1 change in the number of BHFs holdings: -4
Q2-Q1 change in the sum of % ownership for all BHFs combined: -15
✅ 1 Drug approved:
→ RYTELO / Myelodysplastic syndromes (MDS) / June 2024
👨🔬 4 Noteworthy clinical trials:
→ Imetelstat / Myelofibrosis (MF) / Phase 3 (IMpactMF)
→ Imetelstat + Ruxolitinib / MF / Phase 1 (IMproveMF)
→ Imetelstat / R/R AML & HR-MDS / Phase 2 (IMpress)
→ Imetelstat / R/R AML / Phase 1 (TELOMERE)
🧪 MOA: Imetelstat is small molecule telomerase inhibitor
🗓️ Next readout:
→ early 2026: Interim Analysis (Ph3 IMpactMF)
→ early 2027: Final Analysis (Ph3 IMpactMF)
✨ Join BPIQ Premium now to view data on all 34 biopharma-focused hedge funds (BHFs).
BPIQ Premium Let's You:
Search and filter all PDUFA/Catalyst events.
Unlock Big Mover stocks - a list of major catalysts.
Get Investment ideas from our bio hedge fund portfolios.
This article is not investment, tax, or legal advice. Please do your own diligence and seek advice from professional advisors representing your interests.
Article history:
First published 09/06/24 AV & EJV
#ERAS #CTNM #ELYM #SKYE #APLS #KYTX #GERN